DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer
Denis Velic,
Anthony M. Couturier,
Maria Tedim Ferreira,
Amélie Rodrigue,
Guy G. Poirier,
Fabrice Fleury,
Jean-Yves Masson
Affiliations
Denis Velic
Genome Stability Laboratory, CHU de Québec Research Center, HDQ Pavilion, Oncology Axis, 9 McMahon, Québec City, QC G1R-2J6, Canada
Anthony M. Couturier
Genome Stability Laboratory, CHU de Québec Research Center, HDQ Pavilion, Oncology Axis, 9 McMahon, Québec City, QC G1R-2J6, Canada
Maria Tedim Ferreira
Department of Molecular Biology, Medical Biochemistry and Pathology, Centre de Recherche sur le Cancer, Laval University, Québec City, QC G1V-0A6, Canada
Amélie Rodrigue
Genome Stability Laboratory, CHU de Québec Research Center, HDQ Pavilion, Oncology Axis, 9 McMahon, Québec City, QC G1R-2J6, Canada
Guy G. Poirier
Department of Molecular Biology, Medical Biochemistry and Pathology, Centre de Recherche sur le Cancer, Laval University, Québec City, QC G1V-0A6, Canada
Fabrice Fleury
DNA repair regulation team, UFIP, CNRS UMR 6286, Université de Nantes, 2 rue de la Houssinière, Nantes 44322, France
Jean-Yves Masson
Genome Stability Laboratory, CHU de Québec Research Center, HDQ Pavilion, Oncology Axis, 9 McMahon, Québec City, QC G1R-2J6, Canada
For decades, radiotherapy and chemotherapy were the two only approaches exploiting DNA repair processes to fight against cancer. Nowadays, cancer therapeutics can be a major challenge when it comes to seeking personalized targeted medicine that is both effective and selective to the malignancy. Over the last decade, the discovery of new targeted therapies against DNA damage signalling and repair has offered the possibility of therapeutic improvements in oncology. In this review, we summarize the current knowledge of DNA damage signalling and repair inhibitors, their molecular and cellular effects, and future therapeutic use.